

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Result of Annual General Meeting

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer[®] and pre|CISION[™] platforms, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today.

The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2021 Annual Report, which is available under the Investor Documents & Presentations section of the Company's website www.avacta.com.

The non-material presentation provided to shareholders can be found under the Investor Documents & Presentations section of the Company's website www.avacta.com.

– ENDS –

For further information from Avacta Group plc, please contact:**Avacta Group plc**

Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications Director

Tel: +44 (0) 1904 21 7070
www.avacta.com

Stifel Nicolaus Europe Limited (Nomad and Broker)

Nicholas Moore / Nick Adams / Fred Walsh / Nicholas Harland

Tel: +44 (0) 207 710 7600
www.stifel.com

FTI Consulting (Financial Media and IR)

Simon Conway / Alex Shaw / George Kendrick

Tel: +44(0) 203 727 1000
Avacta.LS@fticonsulting.com

Zyme Communications (Trade and Regional Media)

Lily Jeffery

Tel: +44 (0)7891 477 378
lily.jeffery@zymecom munications.com

About Avacta Group plc - www.avacta.com

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer[®] biologics and pre|CISION[™] tumour targeted chemotherapies.

The Affimer[®] platform is an alternative to antibodies and is derived from a small human protein. Affimer technology has been designed to address many of the negative issues of antibodies, principally: the time taken to generate new antibodies, the reliance on an animal's immune response; poor specificity in many cases; in addition to, the complexity and high cost of manufacture. Despite these shortcomings,

antibodies currently dominate markets, such as diagnostics and therapeutics, which are worth in excess of \$100bn.

Avacta's pre|CISION™ targeted chemotherapy platform is designed to selectively release active chemotherapy in FAP rich tumour tissue to limit the systemic exposure that causes damage to healthy tissues, and thereby aims to improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.

The Avacta Group comprises two divisions: The therapeutics development activities are based in London, UK and a separate diagnostics business unit is based in Wetherby, UK. The Group is generating near-term revenues from Affimer® reagents for diagnostics, bioprocessing and research.

Avacta's Diagnostics Division is developing an in-house pipeline of Affimer-based diagnostic assays, including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test, and works with partners worldwide to develop bespoke Affimer® reagents for third party products.

Avacta's Therapeutics Division is working to generate more tolerable and durable treatments for oncology patients who do not respond to existing therapies. By combining its two proprietary platforms the Group is building a wholly owned pipeline of clinically differentiated cancer therapies. In 2021 Avacta transitioned to become a clinical stage biopharmaceutical company, when it commenced a phase I trial in patients with locally advanced or metastatic selected solid tumours. The study was a first-in-human, open label, dose-escalation and expansion study of the Group's lead pre|CISION™ prodrug, AVA6000 (a pro-doxorubicin).

Avacta has established drug development partnerships with pharma and biotech, including a multi-target deal with LG Chem worth up to \$400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators and a recent license agreement with Point Biopharma for them to develop radiopharmaceuticals based on the pre|CISION™ platform.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts